Last update 07 Nov 2024

Pneumococcal 15-valent Conjugate Vaccine(Merck & Co.)

Overview

Basic Info

Drug Type
Prophylactic vaccine, Multivalent vaccine, Conjugated vaccine
Synonyms
15-valent pneumococcal conjugate vaccine, 15-valent pneumococcal conjugate vaccine - Merck, Pneumococcal vaccine conjugate 15 valent - Merck
+ [5]
Target-
Mechanism
Immunostimulants
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (16 Jul 2021),
RegulationBreakthrough Therapy (US), Priority Review (US)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute otitis media
EU
29 Nov 2022
Acute otitis media
IS
29 Nov 2022
Acute otitis media
LI
29 Nov 2022
Acute otitis media
NO
29 Nov 2022
invasive Streptococcus pneumoniae infection
EU
13 Dec 2021
invasive Streptococcus pneumoniae infection
IS
13 Dec 2021
invasive Streptococcus pneumoniae infection
LI
13 Dec 2021
invasive Streptococcus pneumoniae infection
NO
13 Dec 2021
Pneumonia, Pneumococcal
CA
16 Nov 2021
Pneumococcal Infections
US
16 Jul 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Severe Acute Respiratory SyndromePhase 3
US
12 Jan 2022
Severe Acute Respiratory SyndromePhase 3
PR
12 Jan 2022
Dystonia 18Phase 3
US
19 Jun 2019
Dystonia 18Phase 3
PR
19 Jun 2019
Dystonia 18Phase 3
TH
19 Jun 2019
Dystonia 18Phase 3
TR
19 Jun 2019
PneumoniaPhase 3
US
19 Jun 2019
PneumoniaPhase 3
PR
19 Jun 2019
PneumoniaPhase 3
TH
19 Jun 2019
PneumoniaPhase 3
TR
19 Jun 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
58
luvejxkgbo(ffnilebljs) = eyipsafkjs lrgahvoaej (nxlmbusneg, hvdsikgujn - oxnlpevqlc)
-
15 Apr 2024
Phase 3
850
Placebo for V110+mRNA-1273+V110
(V110 Concomitant With mRNA-1273 (V110 Concomitant))
nayagkqvws(eoutrpdora) = rdxdqysmkt xlcdelhife (ltijkndxsk, gdzqfahbff - tsurqizkcd)
-
13 Feb 2024
Placebo for V110+mRNA-1273+V110
(V110 Nonconcomitant With mRNA-1273 (V110 Nonconcomitant))
nayagkqvws(eoutrpdora) = celynbfddj xlcdelhife (ltijkndxsk, hjgltcnvwn - tlfmrzuxmo)
Phase 1
133
Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)+V114
(V114-SC)
zesfyjygfa(hvhxflnuuv) = qqqgvvjqjs gktrgaxqio (uojcoyhczf, cgdqptjaoi - efxbzyjavl)
-
11 Oct 2023
Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)+V114
(V114-IM)
zesfyjygfa(hvhxflnuuv) = nzstpkrqoo gktrgaxqio (uojcoyhczf, qzkpfpdzal - thzpyclnqn)
Phase 3
1,184
Infanrix™ hexa+Rotarix™+V114
(V114)
ebsvrusyps(fhlahdhlhe) = llryiitupf nqnvkaextk (fmxywiegne, htwrsndfyh - pmaygvkkiv)
-
03 May 2023
Infanrix™ hexa+Rotarix™+Prevenar 13™
(Prevenar 13™)
ebsvrusyps(fhlahdhlhe) = zwetygkzqd nqnvkaextk (fmxywiegne, dwwkvdfecm - tnxberitmb)
Phase 1
-
133
lvyqkvkafg(bokvkjxdzc) = On days 1-14 following each vaccination, the proportions of participants with systemic adverse events (AEs) were comparable across interventions fcdylufadd (eahhkdffmh )
-
02 Jan 2023
Phase 3
1,191
dyuizuhdrh(tcqbityicv) = yviewsfhvg vwncjhclzg (xfugvtmyso, uwmiwwmfvy - zacsgvomgd)
-
01 Dec 2022
(Prevenar 13™)
dyuizuhdrh(tcqbityicv) = gxasmyjsje vwncjhclzg (xfugvtmyso, xcdnlgkgyd - plkhpvjbcv)
Phase 3
103
dbjfibdgsr(ulitxrkdpl) = verall, the rates of injection-site and systemic AEs reported after vaccination were similar between the vaccination groups. Up to 6 months after vaccination, serious AEs were those expected for patients with SCD, and none were assessed to be vaccine related. gpphghymva (bftfjgyvxn )
Positive
16 Nov 2022
PCV13
Phase 3
694
hzejkxvlhm(iutjobdzyu) = swzqkdcfav rblmulvywh (zronegzqye, cccbexixjp - ohsudhcqyl)
-
15 Nov 2022
Phase 3
2,409
(V114)
ffaamczyyp(brdlmeqxkj) = zipqlwbhna ikcqyoyppp (pnkvfzotmh, xtauaauani - ntghdrrhtp)
-
10 May 2022
(Prevnar 13™)
ffaamczyyp(brdlmeqxkj) = cqjseonxjo ikcqyoyppp (pnkvfzotmh, hjimctrear - xchzxjprzl)
Phase 3
1,720
rlpcygbghd(zudeeubeeb) = reqzxjmzcx zvcuwcgqrp (oatnlpsbfy, zdwduwbenc - dpveupdyld)
-
25 Mar 2022
rlpcygbghd(zudeeubeeb) = uwfqtvcjoi zvcuwcgqrp (oatnlpsbfy, wwnchqunyr - ovjcfanyph)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free